{
  "success": true,
  "sourceFile": "input/Alexion_NCT04573309_Wilsons_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Screened Set",
        "text": "All participants who signed an informed consent form and check-in to the clinical research unit (CRU) on Day -8 for the Run-in Period.",
        "populationType": "Other",
        "instanceType": "AnalysisPopulation",
        "label": "Screened Set",
        "populationDescription": "All participants who signed an informed consent form and check-in to the clinical research unit (CRU) on Day -8 for the Run-in Period.",
        "criteria": "Signed ICF AND checked into CRU on Day -8"
      },
      {
        "id": "pop_2",
        "name": "Enrolled Set",
        "text": "Participants eligible for the study who are enrolled on Day -7 and initiated on a copper- and molybdenum-controlled diet.",
        "populationType": "Other",
        "instanceType": "AnalysisPopulation",
        "label": "Enrolled Set",
        "populationDescription": "Participants eligible for the study who are enrolled on Day -7 and initiated on a copper- and molybdenum-controlled diet.",
        "criteria": "Eligible AND enrolled on Day -7 AND initiated on controlled diet"
      },
      {
        "id": "pop_3",
        "name": "Full Analysis Set",
        "text": "The primary analysis set used to describe the second and subsequent analysis of interim data from Study ALXN1840-WD-204 to support regulatory submissions, typically including all enrolled participants with Wilson Disease (WD) who receive study treatment.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FA",
        "populationDescription": "The primary analysis set used to describe the second and subsequent analysis of interim data from Study ALXN1840-WD-204 to support regulatory submissions, typically including all enrolled participants with Wilson Disease (WD) who receive study treatment.",
        "criteria": "Enrolled AND diagnosed with Wilson Disease AND treated with ALXN1840"
      },
      {
        "id": "pop_4",
        "name": "Per Protocol Set",
        "text": "A subset of the Full Analysis Set used for sensitivity analyses, requiring a minimum of at least 3 participants for analysis to be performed.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PP",
        "populationDescription": "A subset of the Full Analysis Set used for sensitivity analyses, requiring a minimum of at least 3 participants for analysis to be performed.",
        "criteria": "Subset of FA AND no major protocol deviations AND N >= 3"
      },
      {
        "id": "pop_5",
        "name": "Safety Set",
        "text": "All participants for whom safety data is reviewed by the SRC, including those who receive ALXN1840 doses of 15 mg/day and 30 mg/day.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "Safety Set",
        "populationDescription": "All participants for whom safety data is reviewed by the SRC, including those who receive ALXN1840 doses of 15 mg/day and 30 mg/day.",
        "criteria": "Received at least one dose of study drug"
      },
      {
        "id": "pop_6",
        "name": "Pharmacokinetic Analysis Set",
        "text": "Participants who have blood sampling for pharmacokinetic (PK) concentration analyses over the 24-hour dosing period on Days 1, 25, 29, and 39, including pre-dose samples during accumulation and at steady state.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PK Analysis Set",
        "populationDescription": "Participants who have blood sampling for pharmacokinetic (PK) concentration analyses over the 24-hour dosing period on Days 1, 25, 29, and 39, including pre-dose samples during accumulation and at steady state.",
        "criteria": "Received study drug AND has evaluable PK blood samples"
      },
      {
        "id": "pop_7",
        "name": "Pharmacodynamic Analysis Set",
        "text": "Participants who have blood sampling for pharmacodynamic (PD) concentration analyses over the 24-hour dosing period on Days 1, 25, 29, and 39, including assessments of plasma total and labile bound copper (LBC).",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PD Analysis Set",
        "populationDescription": "Participants who have blood sampling for pharmacodynamic (PD) concentration analyses over the 24-hour dosing period on Days 1, 25, 29, and 39, including assessments of plasma total and labile bound copper (LBC).",
        "criteria": "Received study drug AND has evaluable PD blood samples"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age at baseline in years"
      },
      {
        "id": "char_2",
        "name": "Wilson Disease History",
        "code": "WILSON_DISEASE_HISTO",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Wilson Disease History",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "History of Wilson Disease (WD) including treatment-experienced and treatment-na√Øve status"
      },
      {
        "id": "char_3",
        "name": "Body Mass Index",
        "code": "BODY_MASS_INDEX",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Body Mass Index",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Body mass index calculated at baseline"
      },
      {
        "id": "char_4",
        "name": "Prior WD Medications",
        "code": "PRIOR_WD_MEDICATIONS",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Prior WD Medications",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Prior medications used to treat Wilson Disease"
      }
    ],
    "summary": {
      "populationCount": 7,
      "characteristicCount": 4
    }
  }
}